Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Clinical trial NCT01650805 · TERMINATED
Trial details
- NCT number
- NCT01650805
- Sponsor
- Ariad Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2012-06-01
- Primary completion
- 2013-10-01
- Enrollment
- 307
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.